We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
51
Kiniksa Pharmaceuticals
KNSA
$6.09B
$26.9M 0.5%
420,600
+240,001
+133% +$12.4M
TRVI icon
52
Trevi Therapeutics
TRVI
$2.39B
$26.7M 0.49%
1,430,293
-1,024,107
-42% -$14.9M
ABVX
53
CALL
Abivax
ABVX
$9.89B
$26.7M 0.49%
+200,000
New +$22.6M
IRON icon
54
Disc Medicine
IRON
$3.07B
$26.2M 0.48%
357,535
-710,015
-67% -$48.8M
WST icon
55
West Pharmaceutical
WST
$23.7B
$25.3M 0.47%
+70,600
New +$21.6M
RLMD icon
56
Relmada Therapeutics
RLMD
$462M
$25.1M 0.47%
3,631,195
-1,084,669
-23% -$7.58M
URGN icon
57
UroGen Pharma
URGN
$2.13B
$24.9M 0.46%
676,187
-199,300
-23% -$5.4M
STRO icon
58
Sutro Biopharma
STRO
$339M
$24.7M 0.46%
743,944
-57,200
-7% -$1.78M
SVRA icon
59
Savara
SVRA
$1.08B
$24.4M 0.45%
3,959,900
+3,324,900
+524% +$17.8M
NPCE icon
60
Neuropace
NPCE
$495M
$23.9M 0.44%
1,505,125
-591,402
-28% -$9.52M
AURA icon
61
Aura Biosciences
AURA
$767M
$23.7M 0.44%
+3,333,333
New +$23.8M
ORIC icon
62
Oric Pharmaceuticals
ORIC
$1.37B
$21.8M 0.4%
2,015,000
-678,929
-25% -$6.16M
HELP
63
Cybin Inc
HELP
$890M
$21.6M 0.4%
3,271,400
-561,443
-15% -$2.81M
BCRX icon
64
BioCryst Pharmaceuticals
BCRX
$2.51B
$18.5M 0.34%
1,852,000
+426,800
+30% +$3.86M
BIOA
65
BioAge Labs
BIOA
$443M
$18.4M 0.34%
752,153
+40,342
+6% +$729K
PTGX icon
66
CALL
Protagonist Therapeutics
PTGX
$9.34B
$18.4M 0.34%
+150,000
New +$15.7M
LXEO icon
67
Lexeo Therapeutics
LXEO
$399M
$18.4M 0.34%
3,947,850
+345,400
+10% +$1.87M
WHWK
68
Whitehawk Therapeutics
WHWK
$263M
$18M 0.33%
3,934,296
-231,704
-6% -$964K
DFTX
69
Definium Therapeutics
DFTX
$5.51B
$17.2M 0.32%
365,400
-438,600
-55% -$10.8M
SYRE icon
70
Spyre Therapeutics
SYRE
$7.97B
$16.5M 0.31%
+186,145
New +$13.6M
CRBP icon
71
Corbus Pharmaceuticals
CRBP
$211M
$16.3M 0.3%
1,737,287
– –
VERA icon
72
Vera Therapeutics
VERA
$2.46B
$15.9M 0.29%
369,596
– –
ALMS
73
Alumis Inc
ALMS
$2.9B
$15.4M 0.29%
548,163
– –
EYPT icon
74
EyePoint Inc
EYPT
$386M
$15.3M 0.28%
1,069,147
– –
WAT icon
75
Waters Corp
WAT
$40.7B
$15.1M 0.28%
+40,300
New +$13.7M
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.